Breast Cancer Research and Treatment

, Volume 116, Issue 3, pp 529–530 | Cite as

Does hormonal therapy decrease tamoxifen associated hot flashes?

  • Debra L. Barton
  • Charles L. Loprinzi
Invited Commentary

The manuscript by Osborne et al. [1] addresses the question of whether hormonal therapy will decrease hot flashes in patients receiving tamoxifen. Managing hot flushes is important as they are a very challenging side effect of tamoxifen which can negatively impact various areas of a woman’s life; including sleep and relationships.

One of the important aspects of this manuscript regards the role of hot flashes in motivating women to start hormone therapy as well as to stop taking tamoxifen. As an example, in this study the authors report 22 patients who withdrew from the trial related to severe hot flashes. This information leads to a critical point, that being the need to assertively evaluate and manage hot flashes and other related side effects of tamoxifen or any other pharmacologic treatment, whether the purpose of that medication is to prevent or to treat cancer.

Whether hot flash therapies work to different degrees in patients receiving tamoxifen, compared to those who are not...


Tamoxifen Hormonal Therapy Medroxyprogesterone Acetate Receive Hormone Therapy Progestogen Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O’Shaughnessy JA (2009) The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-008-0284-y
  2. 2.
    Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C (2009) Efficacy of non-estrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause (in press)Google Scholar
  3. 3.
    Loprinzi C, Zahasky K, Sloan J, Novotny P, Quella S (2000) Tamoxifen-induced hot flashes. Clin Breast Cancer 1(1):52–56. doi: 10.3816/CBC.2000.n.004 PubMedCrossRefGoogle Scholar
  4. 4.
    Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J (2006) Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 24(24):3991–3996. doi: 10.1200/JCO.2005.04.3745 PubMedCrossRefGoogle Scholar
  5. 5.
    Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE et al (1994) Megestrol acetate for the prevention of hot flashes. N Engl J Med 331(6):347–352. doi: 10.1056/NEJM199408113310602 PubMedCrossRefGoogle Scholar
  6. 6.
    Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR et al (2006) Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7. J Clin Oncol 24(9):1409–1414. doi: 10.1200/JCO.2005.04.7324 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  1. 1.Department of OncologyMayo ClinicRochesterUSA

Personalised recommendations